Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease

October 25, 2019 updated by: St. Joseph's Hospital and Medical Center, Phoenix

Clinical Protocol of a Prospective, Open-label Study to Assess the Safety and Efficacy of Nuedexta (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Alzheimer's Disease

The primary objective of this study is to test the hypothesis that Nuedexta (20/10) administered orally will reduce Pseudobulbar Affect (PBA) frequency and severity (CNS-Lability Scale and PLACS), with satisfactory safety and high tolerability in patients with Alzheimer's Disease (AD). The primary objective will be evaluated using a study endpoint at 1, 13, 26 weeks after initiation of treatment. The secondary objective of this study is to evaluate the benefit of treatment with Nuedexta (20/10) on cognition and functionality as demonstrated in the Rey Auditory Verbal Learning Test (RAVLT), Trail making A and B, Wechsler Memory Scale (WMS) logical memory and delayed recall, Controlled Oral Word Association (COWA), Clinical Dementia Rating (CDR), Neuropsychiatric Inventory (NPI), Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCSADL) and the 11-item Alzheimer's Disease Assessment Scale-Cognitive subscore (ADAS-Cog11).

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Arizona
      • Phoenix, Arizona, United States, 85013
        • Barrow Neurological Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

53 years to 88 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male/female 55 to 90 years, inclusive.
  • Meets National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria for probable AD.
  • Modified Hachinski Ischemia Scale score of ≤4.
  • Folstein Mini Mental State Exam score 16-26 at Visit 1.
  • Geriatric Depression Scale score ≤6. For patient with history of depression, he/she have been on steady dose of anti-depressant for at least 3 months.
  • Clinical history and relevant symptoms of Pseudobulbar Affect.
  • Center for Neurologic Study-Lability Scale score at baseline ≥13.
  • Stable hematologic, hepatic, and renal function, with no clinically significant symptoms, and with clinical laboratory results (CBC, clinical chemistry, and urinalysis) up to 1-fold higher than upper limit of normal range.
  • Resting respiratory rate 12-20/minute.
  • MRI or CT scan within past 12 months; no findings inconsistent with diagnosis of AD.
  • ECG (within 4 weeks prior to entry)with no evidence of clinically significant abnormalities.
  • Concurrent treatment with an acetylcholinesterase inhibitor or memantine allowed; must be on stable dose at least 2 months before screening. Dosing must remain stable throughout the study.
  • Use of SSRI's allowed. Must have used for 3 months prior to study entry; dose must remain unchanged during course of study.
  • No current symptoms of depressive disorder.
  • Score of 19 or lower in the Beck Depression Inventory.
  • Agrees to use no prohibited medications during study.

Exclusion Criteria:

  • Has current serious or unstable illnesses that, in investigator's opinion, could interfere with analysis of safety and efficacy data; has life expectancy <2 years.
  • No reliable caregiver in frequent contact with patient (at least 10 hours/week.
  • Current or prior history of major psychiatric disturbance.
  • Have been in other clinical study within 30 days of entry.
  • Score of 20 or higher in Beck Depression Inventory.
  • Multiple episodes of head trauma, history within last year of serious infectious disease affecting the brain, head trauma resulting in protracted loss of consciousness, or myasthenia gravis.
  • Within the last 5 years, history of a primary or recurrent malignant disease.
  • Known sensitivity to quinidine or dextromethorphan.
  • History of human immunodeficiency virus, multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions.
  • History of chronic alcohol or drug abuse/dependence within the past 5 years.
  • Judged by investigator to be at serious risk for suicide.
  • Has a recent or current lab result indicating clinically significant lab abnormality.
  • At Visit 1 has ALT/SGPT values ≥2 times upper limit of normal (ULN); AST/SGOT values ≥3 times the ULN; total bilirubin values ≥2 times the ULN.
  • Resting diurnal oxygen saturation <95%.
  • Received dextromethorphan and quinidine within previous 6 months.
  • Hypotension (systolic BP <100 mm Hg); postural syncope; unexplained syncope.
  • Used medications that affect the CNS (except for AD) for less than 4 weeks.
  • On disallowed concomitant medications.
  • Experiencing acute exacerbation of underlying neurological disorder within previous 2 months.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Nuedexta (20/10)
Drug: Nuedexta (20/10) administered orally, two times a day (every 12 hours), during a 26-week period.
Drug: Nuedexta (20/10)
Drug: Nuedexta (20/10) administered orally, two times a day, every 12 hours, during a 26-week period.
Other Names:
  • Dextromethorphan/Quinidine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
reduction of PBA frequency
Time Frame: 1, 13, and 26 weeks after initiation of treatment
1, 13, and 26 weeks after initiation of treatment

Secondary Outcome Measures

Outcome Measure
Time Frame
reduction of PBA severity
Time Frame: 1, 13, and 26 weeks after initiation of treatment
1, 13, and 26 weeks after initiation of treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

St. Joseph's Hospital and Medical Center, Phoenix

Collaborators

Avanir Pharmaceuticals

Investigators

  • Principal Investigator: Jiong Shi, MD, PhD, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix AZ

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 28, 2012

Primary Completion (Actual)

December 1, 2015

Study Completion (Actual)

December 1, 2016

Study Registration Dates

First Submitted

April 9, 2013

First Submitted That Met QC Criteria

April 15, 2013

First Posted (Estimate)

April 16, 2013

Study Record Updates

Last Update Posted (Actual)

October 29, 2019

Last Update Submitted That Met QC Criteria

October 25, 2019

Last Verified

October 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AVP923

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer's Disease

Clinical Trials on Nuedexta (20/10)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe